drugset / Trial / NCT07579234
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
RandomizedParallel-groupSingle-blindTreatment
Summary
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing F182112 with Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma
Timeline
- Start
- 2026-01-25
- Primary completion
- 2029-01-25
- Completion
- 2029-01-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bortezomib | Small molecule | — | — |
| Comparator | Dexamethasone | Small molecule | — | — |
| Subject | F182112 | Unknown | — | — |
| Comparator | Pomalidomide | Other / unclassified | — | — |
| Comparator | Selinexor | Other / unclassified | — | — |